The total prevalence of GJB2-dependent HL in Iran is 16.5%; however, it varies in different regions of Iran from 38.3% to zero in the North and South, respectively.1 Regardless of GJB2, SLC26A4 mutations, with a frequency of 16.25%, are the highest contributors to NSHL in the Iranian population.1 Here, GJB2 is linked to Hodgkins lymphoma.